0000890465-14-000004.txt : 20140109 0000890465-14-000004.hdr.sgml : 20140109 20140109164637 ACCESSION NUMBER: 0000890465-14-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140107 FILED AS OF DATE: 20140109 DATE AS OF CHANGE: 20140109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NPS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000890465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870439579 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (908) 450-5300 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nader Francois CENTRAL INDEX KEY: 0001365343 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23272 FILM NUMBER: 14519194 MAIL ADDRESS: STREET 1: 550 HILLS DRIVE CITY: BEDMINSTER STATE: NJ ZIP: 07921 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2014-01-07 0000890465 NPS PHARMACEUTICALS INC NPSP 0001365343 Nader Francois 550 HILLS DRIVE BEDMINSTER NJ 07921 1 1 0 0 President, CEO and Director Stock Option 3.34 2014-01-07 4 A 0 20250 0 A 2020-02-19 Common Stock 20250 216000 D On February 19, 2010, the Reporting Person was granted options to purchase shares of Common Stock under the Issuer's 2005 Omnibus Incentive Plan, which are subject to both performance conditions and time-based vesting. On January 7, 2014, the performance criteria for 20,250 of these options was satisfied when the FDA accepted the BLA for Natpara for the treatment of hypoparathyroidism. As of January 7, 2014, the performance criteria and the time-based criteria for 167,063 of these options has been satisfied. These options will vest and become exercisable based on the following vesting schedule: 25% on each of the first four anniversaries of the date of grant. /s/ Francois Nader, by Edward Stratemeier as attorney-in-fact 2014-01-09